COVID-19 Clinical Trial
— PRECOVIMOfficial title:
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
This prospective cohort of patients, receiving pre exposure prophylaxis by Anti-SARS-CoV-2 Monoclonal Antibodies, is designed to evaluate the treatment protection against SARS-CoV-2 variants of concerns
Status | Recruiting |
Enrollment | 200 |
Est. completion date | October 30, 2024 |
Est. primary completion date | June 26, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults (18 years-old or more) - Patient who received the first administration of Evusheld at 300 mg for less than 4 months and should receive a second dose, according to French recommendations OR Patient scheduled to receive or having received less than a month ago an injection of anti-SARS-CoV-2 monoclonal antibodies, as pre-exposure prophylaxis at 600 mg, according to the French SARS-CoV-2 RT recommendations - qPCR negative at baseline - SARS-CoV-2 RT-qPCR Negative at inclusion - Patients who remain seronegative after a complete COVID-19 vaccination schedule - Immunocompromised patients : Hemopathy : chronic lymphoid leukemia, non hodgkin's lymphoma, HSCT Transplant recipient : kidney, liver, lungs Patients receiving anti CD20 or others immunosuppressor - Life expectancy > 3 months - Social security affiliation - Lack of a legal protection measure - Signed informed consent Exclusion Criteria: - Participation to another clinical study - State medical aid - Ongoing or scheduled plasmapheresis or immunoadsorption - Pregnant / lactating woman - Patient whose isolation period is underway following contact with a confirmed case of SARS-CoV2 infection - Hypersensitivity to one of the active substances or to one of the excipients |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Avicenne | Bobigny |
Lead Sponsor | Collaborator |
---|---|
ANRS, Emerging Infectious Diseases |
France,
de Lamballerie X, Martin-Blondel G, Dupont A, Izopet J, Mentre F, Kamar N, Autran B, Paintaud G, Caillard S, le Bourgeois A, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, Guyen SN, Terrier B, Got — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neutralizing antibody activity | Month 1 | ||
Primary | Neutralizing antibody activity | Month 2 | ||
Primary | Neutralizing antibody activity | Month 3 | ||
Primary | Neutralizing antibody activity | Month 4 | ||
Primary | Neutralizing antibody activity | Month 5 | ||
Primary | Neutralizing antibody activity | Month 6 | ||
Primary | Neutralizing antibody activity | Month 9 | ||
Primary | Neutralizing antibody activity | Month 12 | ||
Secondary | Proportion of subjects who have a positive SARS-CoV-2 RT-qPCR) and symptoms of SARS-CoV-2 infection | Month 12 | ||
Secondary | Proportion of subjects hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection during prophylaxis period | Month 12 | ||
Secondary | Proportion of patients infected with a resistant variant | Month 12 | ||
Secondary | Proportion of patients with treatment AE | Month 12 | ||
Secondary | Severity of treatment AE | Month 12 | ||
Secondary | Proportion of patients with SAE | Month 12 | ||
Secondary | Proportion of patients with suspended prophylaxis due to adverse event | Month 12 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 1 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 2 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 3 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 4 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 5 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 6 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 9 | ||
Secondary | Variability of the individual pharmacokinetic parameters of the two monoclonal antibodies and covariates influencing it | Month 12 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 1 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 2 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 3 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 4 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 5 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 6 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 9 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the levels of anti-S and anti-N antibodies | Month 12 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 1 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 2 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 3 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 4 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 5 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 6 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 9 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the neutralizing activity of the serum towards the omicron variant of SARS-CoV-2 | Month 12 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 1 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 2 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 3 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 4 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 5 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 6 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 9 | ||
Secondary | Relations between the concentrations of the two monoclonal antibodies and the risk of infection by the omicron variant of SARS-CoV-2 | Month 12 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 1 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 2 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 3 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 4 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 5 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 6 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 9 | ||
Secondary | Relationship between the concentrations of the two monoclonal antibodies and the risk of of adverse effects. | Month 12 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 1 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 2 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 3 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 4 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 5 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 6 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 9 | ||
Secondary | Anti-S et Anti- N antibodies levels | Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|